You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
莫德納(MRNA.US)月內在港推出Omicron亞變異株二價加強劑疫苗
阿思達克 09-06 16:18
莫德納(MRNA.US)宣布,旗下針對Omicron亞變異株的二價加強劑疫苗mRNA-1273.222,將於本月在香港上市,本港私家醫院和診所將提供莫德納二價疫苗的接種服務。 莫德納全球高級副總裁兼新興市場總經理Patrick Bergstedt表示,莫德納致力為香港提供更多新冠疫苗選擇,隨著冬季及長假期的來臨,預計染疫率亦隨之上升,而莫德納疫苗在香港上市料將為市民提供有效預防新型冠狀病毒的疫苗選擇。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account